MultiStem, administered intravenously, is an allogeneic cell therapy product candidate which helps promote healing and tissue repair.
The Phase I multi-center dose escalation clinical trial is intended to assess the safety and tolerability of a single or repeat dose administration of allogeneic MultiStem delivered intravenously following a traditional donor-derived hematopoietic stem cell transplant.
The patients received either a low, medium or high dose of MultiStem for both the single and repeat dose arms.
The data is likely to be announced at the end of the year.